Chemotherapy Plus Cetuximab in Patients with Colorectal Metastases Grouped by Site: A Pooled Analysis of the Crystal and OPUS Studies

摘要: ABSTRACT Background In the CRYSTAL and OPUS studies, adding cetuximab to first-line chemotherapy (CT) improved clinical benefit in patients with KRAS wild-type (wt) metastatic colorectal cancer. a pooled analysis of these trials, treatment according whether had liver-limited disease (LLD) or non-LLD was analyzed. Methods Cox's proportional hazards model for overall survival (OS) progression-free (PFS) logistic regression best response R0 resection were used on individual patient data, stratified by study. Likelihood ratio tests explore interactions. Results Adding CT significantly PFS (median 11.9 versus 9.2 months, hazard [HR] 0.53, P = 0.0095) rate (ORR, 72.0 43.2%, odds 3.51, P  Conclusions The OS from is more pronounced patients, thus strengthening value palliative treatment. LLD status associated prognosis may be predictive receiving CT + cetuximab, facilitating potentially curative resection. More (with longer follow-up) needed confirm an CT + cetuximab patients.